Katharina von Baumbach (#607)
- $ 7 B
- Pharma
- Germany
- F
- 26 Years
'A form of double taxation': Are management fees on new houses quietly getting out of control?
Trump Official Blames Biden Admin for Economic ‘Mess’ — As Resurfaced Clip Shows Him Saying Trump Would Own the Economy By 2026
Is Precigen, Inc. (PGEN) A Good Stock To Buy Now?
Is Transocean Ltd. (RIG) A Good Stock To Buy Now?
Tesla is selling Chinese-made cars in Canada to escape the tariffs that both China and America imposed on it
Insecurity didn’t start with Tinubu, group defends president’s security record
Vibrating pillow sleeve warns deaf sleepers of burglars and fires
How Kepler built verifiable AI for financial services with Claude
Is ASML Holding N.V. (ASML) A Good Stock To Buy Now?
5-Letter Words Ending in ‘Y’ to Help You Improve Your Wordle Skills
About Me
Katharina von Baumbach is an heir to the Boehringer Ingelheim fortune, a company best known as the largest private player in the pharmaceutical industry. Founded in 1885, the company grew by making ingredients for pharmacies, textile merchants and the food industry; and boasted a workforce of 1,500 by 1939. Today, Boehringer Ingelheim, whose most well-known drugs treat COPD, anti-coagulation and type 2 diabetes, employs 53,000 people and has a presence in 130 markets.
Achievements
Career Highlights
A snapshot of the defining milestones, leadership decisions, and breakthroughs that shaped Katharina von Baumbach’s rise and global influence.
Wealth Growth
Net Worth Growth Over Time
Tracking Katharina von Baumbach’s net worth journey over the years, highlighting key growth phases and financial milestones.
Current Net Worth: $6.6B
(May 4, 2026)
© Iconic Billionaires